diedhddl
Nov 9, 3:02 AM
$SANA Delivery route is an underrated variable in the T1D cell therapy race.
$IPSC CNTY-813 goes intraportal. That’s the 25-year standard from cadaveric islet transplant, and it works — but it requires interventional radiology or transplant surgery at centers that do islet transplants. There aren’t many of those. Sana’s CEO has cited ~5% hospitalization from clotting or bleeding with the intraportal route as one reason they avoided it.
$SANA SC451 goes intramuscular. Harr’s precedent: parathyroid autotransplant into forearm muscle, ~14,000 times a year in the US, works every time. That’s a procedure a general endocrinology clinic can do.
Neither matters much for Phase 1 — a handful of expert sites is enough either way. It matters for commercial uptake.
$IOVA is the cautionary tale: the data wasn’t the problem, authorized treatment center capacity was. Building centers isn’t a money problem, it’s a time problem.
Not investment advice. I’m long
$SANA.
4 replies